MSC Exosomes for Sepsis & Critical Care
Mesenchymal stem cell (MSC)-derived exosomes are studied in regenerative research for sepsis and critical-illness inflammation. This overview is provided for research and educational purposes only.
What MSC exosomes are
MSC-derived exosomes are nanoscale, cell-free extracellular vesicles (roughly 30–150 nm) that carry signaling cargo such as proteins, lipids, and microRNA. They are not stem cells, and BioRegenEx supplies them as characterized, research-use-only material with per-lot documentation.
What the research explores
In preclinical sepsis and acute lung injury models, MSC-derived exosomes have been studied for anti-inflammatory and tissue-protective signaling. These are research findings only. The studies are indexed in our Exosome Research Library under Sepsis & Critical Care.
Why sourcing and characterization matter
Because exosome composition depends on the source cells and manufacturing, research-grade material is defined by measurement — particle size and concentration, sterility and endotoxin screening, and a per-lot Certificate of Analysis.
Frequently Asked Questions
Are MSC exosomes an approved sepsis treatment?
No. MSC-derived exosomes are not FDA-approved to treat this or any condition and are supplied for research use only (RUO).
What does the research focus on?
Preclinical research focuses on immune modulation and organ-protective signaling.
For research and educational purposes; research-use-only.
These statements have not been evaluated by the FDA. BioRegenEx supplies MSC-derived exosomes for research use only (RUO); they are not intended to diagnose, treat, cure, or prevent any disease. This content is educational and is not medical advice.